Damora Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Damora Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $257.62 million for the year ending 2025.

  • Damora Therapeutics, Inc. showed an increase of +1,717.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,181.1%.
  • Historical annual values: Fiscal year 2025: $257.62 million | Fiscal year 2024: $14.18 million | Fiscal year 2023: $21.47 million | Fiscal year 2022: $32.79 million | Fiscal year 2021: $62.56 million | Fiscal year 2020: $163.58 million | Fiscal year 2019: $11.29 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: